Search alternatives:
"noted decrease" » "showed decreased" (Expand Search)
"fold increased" » "fold increase" (Expand Search), "could increase" (Expand Search)
"fold decrease" » "fold increase" (Expand Search)
Showing 41 - 60 results of 2,406 for search '(((("noted decrease") OR ("fold decrease"))) OR ("fold increased"))', query time: 0.18s Refine Results
  1. 41
    Cox regression models for adverse cardiovascular events (ACE) and individual components of ACE.

    Cox regression models for adverse cardiovascular events (ACE) and individual components of ACE. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 42
    Adverse cardiovascular events by immune checkpoint inhibitor.

    Adverse cardiovascular events by immune checkpoint inhibitor. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 43
    Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events.

    Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 44
    Minimal dataset.

    Minimal dataset. by Jennifer M. Kwan (3350321)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 45
    Baseline characteristics* by NAFLD status in the control group.

    Baseline characteristics* by NAFLD status in the control group. by Mary Cushman (29639)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  6. 46
    Association of AST/ALT >2 with incident cognitive impairment.

    Association of AST/ALT >2 with incident cognitive impairment. by Mary Cushman (29639)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  7. 47
    Inclusion of cases and controls in the analysis of the association of FLI with risk of incident cognitive impairment.

    Inclusion of cases and controls in the analysis of the association of FLI with risk of incident cognitive impairment. by Mary Cushman (29639)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 48
    Odds ratios of cognitive impairment by AST, ALT, and GGT. Quartile cut-off values.

    Odds ratios of cognitive impairment by AST, ALT, and GGT. Quartile cut-off values. by Mary Cushman (29639)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  9. 49
    Odds ratio (95% confidence interval) of cognitive impairment by NAFLD.

    Odds ratio (95% confidence interval) of cognitive impairment by NAFLD. by Mary Cushman (29639)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  10. 50
    Quartile cut-off values.

    Quartile cut-off values. by Mary Cushman (29639)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  11. 51
    Levels of risk factors, NAFLD, and liver biomarkers in incident cognitive impairment cases and controls.

    Levels of risk factors, NAFLD, and liver biomarkers in incident cognitive impairment cases and controls. by Mary Cushman (29639)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  12. 52
    Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides

    Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 53
    Change of % DLCO during the follow-up.

    Change of % DLCO during the follow-up. by Ivan Castellví (4269907)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  14. 54
    S1 File -

    S1 File - by Ivan Castellví (4269907)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  15. 55
    Pulmonary hypertension development during the follow-up in bosentan and in control group.

    Pulmonary hypertension development during the follow-up in bosentan and in control group. by Ivan Castellví (4269907)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  16. 56
    Adverse effects related to bosentan.

    Adverse effects related to bosentan. by Ivan Castellví (4269907)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  17. 57
    Echocardiographic parameters between groups.

    Echocardiographic parameters between groups. by Ivan Castellví (4269907)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  18. 58
    Baseline characteristics.

    Baseline characteristics. by Ivan Castellví (4269907)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  19. 59
    <i>Odds ratio</i> (OR) to no develop pulmonary hypertension on echocardiography during the follow-up.

    <i>Odds ratio</i> (OR) to no develop pulmonary hypertension on echocardiography during the follow-up. by Ivan Castellví (4269907)

    Published 2020
    Subjects:
    Save to List
    Saved in:
  20. 60
    Estimated trends of mortality rate (a, b) and ASMR (c, d) in 2030 (a, c) and 2050 (b, d) at the national level.

    Estimated trends of mortality rate (a, b) and ASMR (c, d) in 2030 (a, c) and 2050 (b, d) at the national level. by Qingsong Mao (19522438)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: